loading

Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie

pulisher
May 05, 2026

Cartesian Therapeutics Inc (RNAC) - MSN

May 05, 2026
pulisher
May 04, 2026

Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times

May 04, 2026
pulisher
May 04, 2026

Five new Cartesian hires get stock options priced at $6.22 - Stock Titan

May 04, 2026
pulisher
May 02, 2026

CARTESIAN THERAPEUTICS, INC. (RNAC) - MSN

May 02, 2026
pulisher
May 01, 2026

RNAC Reiterated by Cartesian Therapeutics -- Price Target Mainta - GuruFocus

May 01, 2026
pulisher
May 01, 2026

Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat

May 01, 2026
pulisher
Apr 30, 2026

Cartesian Therapeutics (NASDAQ:RNAC) Posts Quarterly Earnings Results - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

Cartesian Therapeutics, Inc. Q1 2026 Financial Report: Forward-Looking Statements, Risks, and Financial Results - Minichart

Apr 30, 2026
pulisher
Apr 30, 2026

Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

Cartesian Therapeutics Reports Q1 2026 Financial Results and Advances Descartes-08 Clinical Trials in Autoimmune Diseases - Minichart

Apr 30, 2026
pulisher
Apr 30, 2026

Cartesian Therapeutics, Inc. (RNAC) reports Q1 loss, lags revenue estimates - MSN

Apr 30, 2026
pulisher
Apr 30, 2026

Myasthenia Gravis Market: Fast-Growing Therapeutics Outlook by 2034 – DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - Barchart.com

Apr 30, 2026
pulisher
Apr 30, 2026

Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Apr 30, 2026
pulisher
Apr 30, 2026

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times

Apr 30, 2026
pulisher
Apr 30, 2026

8-K: Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updatemoomoo - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

Cartesian Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

Cartesian Therapeutics posts first quarter 2026 financial results and issues business update - Traders Union

Apr 30, 2026
pulisher
Apr 30, 2026

Cartesian Therapeutics (RNAC) widens Q1 loss as R&D rises but cash tops $120M - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Deeper Q1 loss as Cartesian (NASDAQ: RNAC) funds Descartes-08 trials - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

Is Cartesian Therapeutics (RNAC) 1371.4% Overvalued After Q1 202 - GuruFocus

Apr 30, 2026
pulisher
Apr 28, 2026

Cartesian Therapeutics | DEFA14A: Others - Moomoo

Apr 28, 2026
pulisher
Apr 28, 2026

Cartesian Therapeutics | DEF 14A: Definitive information statements - Moomoo

Apr 28, 2026
pulisher
Apr 28, 2026

Form DEFA14A Cartesian Therapeutics, - StreetInsider

Apr 28, 2026
pulisher
Apr 28, 2026

Executive pay, director votes and auditor for Cartesian Therapeutics (NASDAQ: RNAC) - Stock Titan

Apr 28, 2026
pulisher
Apr 24, 2026

RNAC Technical Analysis | Trend, Signals & Chart Patterns | CARTESIAN THERAPEUTICS INC (NASDAQ:RNAC) - ChartMill

Apr 24, 2026
pulisher
Apr 23, 2026

Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet - Seeking Alpha

Apr 23, 2026
pulisher
Apr 23, 2026

Is Cartesian Therapeutics (RNAC) stock a good pick for capital allocation | Q4 2025: EPS Misses ViewsDebt Analysis - Xã Thanh Hà

Apr 23, 2026
pulisher
Apr 21, 2026

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Apr 21, 2026
pulisher
Apr 20, 2026

Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock? - Yahoo Finance

Apr 20, 2026
pulisher
Apr 20, 2026

Cartesian Therapeutics (RNAC) Stock Underweight (Underperforming) 2026-04-20Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026
pulisher
Apr 18, 2026

Cartesian Therapeutics (RNAC) Stock Abandons Cartesian Therapeutics (RNAC) Stock (Eye on Rally) 2026-04-18Vega Volatility - UBND thành phố Hải Phòng

Apr 18, 2026
pulisher
Apr 18, 2026

Cartesian Therapeutics (NASDAQ:RNAC) Trading 10.3% HigherTime to Buy? - MarketBeat

Apr 18, 2026
pulisher
Apr 15, 2026

Cartesian Therapeutics (RNAC) Stock Prediction: What's Next (Drops Sharply) 2026-04-15Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai

Apr 15, 2026
pulisher
Apr 15, 2026

Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.

Apr 15, 2026
pulisher
Apr 13, 2026

Published on: 2026-04-14 00:35:15 - baoquankhu1.vn

Apr 13, 2026
pulisher
Apr 12, 2026

Needham Virtual Healthcare Conference features Cartesian Therapeutics fireside chat on cell therapy - Traders Union

Apr 12, 2026
pulisher
Apr 10, 2026

Chart Watch: What chart patterns are forming on Cartesian Therapeutics IncGap Up & Long-Term Growth Plans - baoquankhu1.vn

Apr 10, 2026
pulisher
Apr 08, 2026

Today's Analyst Ratings: Needham Reiterates Buy Rating for RNAC - GuruFocus

Apr 08, 2026
pulisher
Apr 07, 2026

If You Invested $1,000 in Cartesian (RNAC) - Stock Titan

Apr 07, 2026
pulisher
Apr 06, 2026

Trust linked to Cartesian Therapeutics (RNAC) converts preferred into common - Stock Titan

Apr 06, 2026
pulisher
Apr 06, 2026

Trust linked to RNAC holder Kalayoglu converts preferred into 758,001 common shares - Stock Titan

Apr 06, 2026
pulisher
Apr 06, 2026

Cartesian Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Kalayoglu Murat - Moomoo

Apr 06, 2026
pulisher
Apr 02, 2026

Near-20% holder updates Cartesian Therapeutics (RNAC) stake and board role - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

RNAC SEC FilingsCartesian 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Is Cartesian Therapeutics (RNAC) Stock Good for Beginners | Price at $6.26, Down 2.03%Community Chart Signals - Cổng thông tin điện tử tỉnh Lào Cai

Apr 02, 2026
pulisher
Apr 01, 2026

Published on: 2026-04-01 20:53:55 - baoquankhu1.vn

Apr 01, 2026
pulisher
Mar 31, 2026

Big Money Moves: Should I invest in Cartesian Therapeutics Inc before earningsEarnings Summary Report & Smart Allocation Stock Tips - baoquankhu1.vn

Mar 31, 2026
pulisher
Mar 31, 2026

RNAC Technical Analysis & Stock Price Forecast - Intellectia AI

Mar 31, 2026
pulisher
Mar 31, 2026

Inflation Data: Does Cartesian Therapeutics Inc have declining or rising EPSMarket Weekly Review & Technical Buy Zone Confirmation - baoquankhu1.vn

Mar 31, 2026
pulisher
Mar 31, 2026

Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation - The Globe and Mail

Mar 31, 2026
pulisher
Mar 30, 2026

Merger Talk: Will Cartesian Therapeutics Inc outperform the market in YEAR2026 EndofYear Setup & Entry Point Confirmation Signals - baoquankhu1.vn

Mar 30, 2026
pulisher
Mar 30, 2026

Cartesian Therapeutics board member Murat Kalayoglu to resign effective March 31 - Investing.com UK

Mar 30, 2026
pulisher
Mar 30, 2026

Cartesian Therapeutics board member Murat Kalayoglu to resign effective March 31 By Investing.com - Investing.com South Africa

Mar 30, 2026
pulisher
Mar 30, 2026

Murat Kalayoglu to Resign from Cartesian Board, Leaving Science & Technology Committee - TradingView

Mar 30, 2026
pulisher
Mar 30, 2026

Board member Murat Kalayoglu to leave Cartesian Therapeutics (RNAC) board March 31, 2026 - Stock Titan

Mar 30, 2026
pulisher
Mar 28, 2026

Treasury Yields: Why is Cartesian Therapeutics Inc stock going down2026 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn

Mar 28, 2026
pulisher
Mar 27, 2026

Energy Moves: Is Cartesian Therapeutics Inc benefiting from interest rate changesMarket Activity Recap & Weekly Watchlist for Hot Stocks - baoquankhu1.vn

Mar 27, 2026
$28.50
price up icon 0.78%
$50.76
price up icon 2.57%
$92.69
price down icon 3.01%
$138.73
price down icon 1.11%
$147.88
price down icon 0.02%
ONC ONC
$305.60
price up icon 2.86%
Capitalizzazione:     |  Volume (24 ore):